A new 2-pyrrolidinone from Cladosporium sp. associated with Rubus tephrodes

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-10-17 DOI:10.1016/j.phytol.2024.09.005

Shuaixing Liu , Jiaqi Liu , Liangrui Yang , Shengqi Zhang , Fengmei Zhang , Le Cai

引用次数: 0

Abstract

The cultivation of Cladosporium sp., a fungus found in association with Rubus tephrodes Hance, resulted in the identification of sixteen compounds. New compound cladosporlactam (1) was distinguished by featuring a skeleton linked to a furan unit, with 3,4-dihydroxypyrrolidine-2-ketone as its characteristic structure. The structure of cladosporlactam was elucidated through meticulous analyses using NMR, electronic circular dichroism (ECD) calculations. Compound 1 could cause a gradual reduction in lipid droplets in a dose-dependent manner without inducing cytotoxicity and demonstrated intermediate antimicrobial activity against Staphylococcus aureus with MIC values of 8 μg/mL.

查看原文本刊更多论文

一种新的 2-吡咯烷酮，来自与鹅掌楸相关的 Cladosporium sp.

通过对与红宝石（Rubus tephrodes Hance）伴生的 Cladosporium sp.新化合物克拉多孢子内酰胺（1）的特点是骨架与一个呋喃单元相连，其特征结构是 3,4-二羟基吡咯烷-2-酮。通过使用核磁共振、电子圆二色性（ECD）计算进行细致分析，阐明了克拉多孢霉烯内酰胺的结构。化合物 1 能以剂量依赖的方式使脂滴逐渐减少，而不会引起细胞毒性，对金黄色葡萄球菌具有中等抗菌活性，其 MIC 值为 8 μg/mL。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.